With only a few more trading days left in the year it looks like public biotechnology companies will eke out a small collective gain of about 7 percent – a far different scenario than they could have anticipated at the beginning of the year when the biotech sector roared into 2015 on a high, remaining a hot commodity among investors who continued to fuel its five-year bull run. Read More
